Burkina Faso vs Tajikistan: Average cost of multi drug-resistant tuberculosis treatment
Burkina Faso
159 constant 2022 US$
in 2024
Tajikistan
257 constant 2022 US$
in 2024
Burkina Faso rank
91st
Tajikistan rank
90th
Average cost of multi drug-resistant tuberculosis treatment over time
- Burkina Faso
- Tajikistan
How they compare
Tajikistan currently reports 257 constant 2022 US$ against 159 constant 2022 US$ in Burkina Faso, a difference of 98 constant 2022 US$.
That makes Tajikistan's figure about 1.6 times Burkina Faso's.
Across all 8 years both countries report, Tajikistan has been ahead every year.
Burkina Faso ranks 91st and Tajikistan ranks 90th of 92 countries.
Tajikistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burkina Faso | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 304.33 constant 2022 US$ | 2,726 constant 2022 US$ | 2,422 constant 2022 US$ | Tajikistan |
| 2020s | 741 constant 2022 US$ | 1,817 constant 2022 US$ | 1,076 constant 2022 US$ | Tajikistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Burkina Faso or Tajikistan?
- Tajikistan, at 257 constant 2022 US$ against 159 constant 2022 US$ in Burkina Faso as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Burkina Faso and Tajikistan?
- 98 constant 2022 US$, with Tajikistan ahead.
- How many years of comparable data are there for Burkina Faso and Tajikistan?
- 8 years are reported by both, from 2017 to 2024.
- How do Burkina Faso and Tajikistan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Burkina Faso ranks 91st and Tajikistan ranks 90th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.